Treatment-related Neuropathy and Breast Cancer Treatment
Chapter 3In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses treatment-related neuropathy, which is a common adverse event among patients being treated for breast cancer. Dr O’Regan discusses options for mitigating this side effect, which can be caused by multiple frequently-used treatments.
2016 SABCS: Clinical Insights for Breast Cancer Treatment
In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses the research most likely to have a clinical impact presented at the 2016 San Antonio Breast Cancer Symposium (SABCS). Highlights include practice-changing findings from 3 trials of endocrine therapy, as well as a study about the use of everolimus with fulvestrant among patients with breast cancer.
HER2-positive Metastatic and Triple-negative Cancer Treatments
In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses emerging treatments for patients with HER2-positive, metastatic breast cancer, as well as those for triple-negative breast cancer. CDK inhibitors and everolimus are among the treatments used for patients with HER2-positive disease, though other drugs are being studied. Dr O’Regan also discusses current research on triple-negative cancer.
Emerging Medicines in Breast Cancer Treatment
In this video, Ruth M. O'Regan, MD, division head of hematology/oncology at the University of Wisconsin Carbone Cancer Center, discusses emerging treatments that are being used for patients with breast cancer, including precision medicine for individualizing cancer treatment, as well as liquid biopsies.
